Business
-
Opiant Pharmaceuticals said that it has terminated an agreement for the use of Bespak’s Unidose Xtra device for delivery of its OPNT003 intranasal nalmefene for the treatment of opioid overdose and has entered into a… Read more . . .
-
CDMO Experic is adding a thin film freezing manufacturing line based on technology owned by TFF Pharmaceuticals at its Cranbury, NJ, USA cGMP facility, according to TFF. Completion of Experic’s TFF line, which adds a… Read more . . .
-
The Cystic Fibrosis Foundation (CFF) has awarded Synspira Therapeutics up to $14 million in additional funding for development of two Synspira candidates including SNSP113, an inhaled polycationic glycopolymer for the treatment of CF. The foundation… Read more . . .
-
Liquidia Technologies said that the US Patent Trial and Appeal Board (PTAB) has issued decisions on two patents related to Tyvaso treprostinil inhalation solution, which is marketed by United Therapeutics for the treatment of pulmonary arterial hypertension… Read more . . .
-
Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company’s Pharmaceutical Technology Center,… Read more . . .
-
A consortium formed by Irish biotech OmniSpirant, nebulizer maker Aerogen, and the National University of Ireland Galway has received a €11.6 million grant from Ireland’s Disruptive Technologies Innovation Fund for development of OS002, an inhaled… Read more . . .
-
Teva Canada has launched the Aermony RespiClick fluticasone propionate DPI for the treatment of asthma, the company said. The inhaler will be available in 55 mcg, 113 mcg, and 232 mcg per actuation versions. According… Read more . . .
-
Starpharma said that it has raised A$45 million and expects to raise another A$5 million from Australian and international investors, with proceeds to be used for development of its SPL7013 astodrimer sodium nasal spray for… Read more . . .
-
AZTherapies said that it has closed a $33.6 million Series C-1 financing that will fund regulatory and pre-commercial activities related to the company’s ALZT-OP1 inhaled cromolyn/oral ibuprofen for Alzheimer’s disease and for development of other… Read more . . .
-
Galecto said that it has completed a $64 million equity financing led by Soleus Capital that will be used to advance several candidates, including GB0139, a galectin-3 inhibitor DPI for the treatment of idiopathic pulmonary… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA